Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573226 | 0.82 | FFAR4 (0.40) | ALDH1A1KMT2AKDM4EMEN1GAA | |
| SCHEMBL11926949 | 0.80 | ALDH1A1 (0.35) | ALDH1A1CYP3A4NQO2ATMCYP19A1 | |
| SCHEMBL15984238 | 0.79 | NQO2 (0.40) | ALDH1A1CYP3A4NQO2ATMCYP19A1 | |
| SCHEMBL12484333 | 0.78 | NPC1 (0.37) | ALDH1A1CYP3A4NQO2CYP19A1KMT2A | |
| SCHEMBL14337778 | 0.78 | NQO2 (0.37) | ALDH1A1CYP3A4NQO2CYP19A1KMT2A | |
| SCHEMBL14363137 | 0.78 | SELL (0.41) | ALDH1A1CYP3A4NQO2ATMCYP19A1 | |
| SCHEMBL4492232 | 0.78 | MAPT (0.35) | ALDH1A1CYP3A4NQO2CYP19A1KMT2A | |
| SCHEMBL12553089 | 0.78 | NPC1 (0.36) | ALDH1A1CYP3A4NQO2CYP19A1KMT2A | |
| SCHEMBL21369363 | 0.78 | NQO2 (0.37) | ALDH1A1CYP3A4NQO2CYP19A1SMN1; SMN2 | |
| SCHEMBL10054020 | 0.78 | ALDH1A1 (0.37) | ALDH1A1CYP3A4NQO2CYP19A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| WO-2022219246-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2022-10-20 | — | — | WO | disclosed |
| US-20210230164-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2017-06-22 | — | — | US | disclosed |
| WO-2015148854-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
| US-8575208-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| WO-2013029548-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-07 | — | — | WO | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-5082848-A | Gastrointestinal disorders | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1992-01-21 | — | — | US | disclosed |
| EP-0331357-A1 | 4-Amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | ALDH1A1 1284/4885CYP3A4 249/4885NQO2 982/4885 |
| US-20210230164-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | TP53, MDM2, TP53BP1 | ALDH1A1 479/4885CYP3A4 881/4885NQO2 385/4885 |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | TP53, MDM2, TP53BP1 | ALDH1A1 549/4885CYP3A4 802/4885NQO2 280/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ALDH1A1 1374/4885CYP3A4 219/4885NQO2 2607/4885 |
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | ALDH1A1 277/4885CYP3A4 374/4885NQO2 1433/4885 |
| US-20170174689-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | ALDH1A1 1900/4885CYP3A4 4235/4885NQO2 2568/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | ALDH1A1 1938/4885CYP3A4 430/4885NQO2 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.